Keywords: kosan, kos-953, ph, anticancer, promise, sweden, biosciences

Kosan's KOS-953: Ph I anticancer promise

Article | 13 June 2005

Sweden's Kosan Biosciences has reported preliminary data on KOS-953, its proprietary formulation of the Hsp90 inhibitor 17-AAG, showing early signs ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Johnson & Johnson

Go to company listing

Related Drugs

bortezomib

Velcade

Go to drug listing